알림

Assembly Biosciences Inc. (ASMB)

NasdaqGS: ASMB · 실시간 가격 · USD

32.13

+2.12 (7.06%)

종가 기준: Aug 19, 2026, 2:28 PM

34.07

+0.68%

애프터마켓: 4:51 PM

7.06% (1D)

매수호가	23.36
시가총액	689M
매출 (ttm)	74.84M
순이익 (ttm)	-42K
베타	1.09
EPS (ttm)	1.24
P/E (ttm)	27.29
선행 P/E	-17.95
P/B (ttm)	2.20
P/S (ttm)	9.21
Earnings Date	n/a

매도호가	39.68
거래량	482,051
평균 거래량 (20일)	228,235
시가	30.00
전일 종가	30.01
일중 범위	30.00 - 33.08
52주 범위	20.23 - 39.71
애널리스트	Strong Buy
목표주가	47.5 (47.84%)
배당	n/a
배당락일	n/a

ASMB 소개

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepa...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 17, 2010

직원 수 73

상장 거래소 NasdaqGS

티커 ASMB

웹사이트 https://www.assemblybio.com

전체 기업 정보

재무 실적

2025년 Assembly Biosciences의 매출은 72.3M로, 전년 28.52M 대비 153.52% 증가했습니다. 순이익은 -6.12M로, -84.76% 감소했습니다.

재무제표

애널리스트 전망

애널리스트 4명의 투자의견을 종합하면 ASMB 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 47.5로, 최근 주가 대비 47.84% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Assembly Biosciences가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $8.21M 예상치 하회 $0, 및 -12.80% 전년 대비 감소.

EPS -0.2 예상치 상회 0.32, 및 84.96% 전년 대비 성장.

뉴스

5일 전 · Zacks

Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +71.43% and +45.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1주 전 · Zacks

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.88% and +9.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2개월 전 · MarketBeat

Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead

Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming de...

2개월 전 · MarketBeat

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indication...

3개월 전 · MarketBeat

Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference

Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing p...

2 페이지 중 1

Assembly Biosciences Inc. (ASMB)